☰

Jeanette L Bertron - Publications

Affiliations: 
2016-2020 Chemistry Vanderbilt University, Nashville, TN 
 2020- University of California, San Francisco, San Francisco, CA 
Tree Info Similar researchers PubMed Report error

7 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2021 Bertron JL, Duvernay MT, Mitchell SG, Smith ST, Maeng JG, Blobaum AL, Davis DC, Meiler J, Hamm HE, Lindsley CW. Discovery and Optimization of a Novel Series of Competitive and Central Nervous System-Penetrant Protease-Activated Receptor 4 (PAR4) Inhibitors. Acs Chemical Neuroscience. PMID 34855359 DOI: 10.1021/acschemneuro.1c00557  0.485
2019 Fulton MG, Bertron JL, Reed CW, Lindsley CW. Formal Total Synthesis of Pericoannosin A. The Journal of Organic Chemistry. PMID 31436090 DOI: 10.1021/Acs.Joc.9B01846  0.419
2019 Engers DW, Melancon BJ, Gregro AR, Bertron JL, Bollinger SR, Felts AS, Konkol LC, Wood MR, Bollinger KA, Luscombe VB, Rodriguez AL, Jones CK, Bubser M, Yohn SE, Wood MW, et al. VU6005806/AZN-00016130, an advanced M positive allosteric modulator (PAM) profiled as a potential preclinical development candidate. Bioorganic & Medicinal Chemistry Letters. PMID 31113706 DOI: 10.1016/J.Bmcl.2019.05.026  0.635
2018 Bertron JL, Cho HP, Garcia-Barrantes PM, Panarese JD, Salovich JM, Nance KD, Engers DW, Rook JM, Blobaum AL, Niswender CM, Stauffer SR, Conn PJ, Lindsley CW. The discovery of VU0486846: steep SAR from a series of M PAMs based on a novel benzomorpholine core. Bioorganic & Medicinal Chemistry Letters. PMID 29754948 DOI: 10.1016/J.Bmcl.2018.05.009  0.522
2018 Rook JM, Bertron JL, Cho HP, Garcia-Barrantes PM, Moran SP, Maksymetz JT, Nance KD, Dickerson JW, Remke DH, Chang S, Harp J, Blobaum AL, Niswender CM, Jones CK, Stauffer SR, et al. A novel M1 PAM VU0486846 exerts efficacy in cognition models without displaying agonist activity or cholinergic toxicity. Acs Chemical Neuroscience. PMID 29701957 DOI: 10.1021/Acschemneuro.8B00131  0.516
2017 Tarr JC, Wood MR, Noetzel MJ, Bertron JL, Weiner RL, Rodriguez AL, Lamsal A, Byers FW, Chang S, Cho HP, Jones CK, Niswender CM, Wood MW, Brandon NJ, Duggan ME, et al. Challenges in the development of an M4 PAM preclinical candidate: The discovery, SAR, and in vivo characterization of a series of 3-aminoazetidine-derived amides. Bioorganic & Medicinal Chemistry Letters. PMID 28522253 DOI: 10.1016/J.Bmcl.2017.05.014  0.674
2016 Bertron JL, Ennis EA, Tarr CJ, Wright J, Dickerson JW, Locuson CW, Blobaum AL, Rook JM, Blakely RD, Lindsley CW. Optimization of the choline transporter (CHT) inhibitor ML352: Development of VU6001221, an improved in vivo tool compound. Bioorganic & Medicinal Chemistry Letters. PMID 27575469 DOI: 10.1016/J.Bmcl.2016.08.062  0.578
Show low-probability matches.